Light-based Immunomodulation for Guarding Against Human Respiratory Tract Infections
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorDavid Moss
About this trial
The purpose of trial is to determine if daily usage of a photobiomodulation device will decrease the incidence of upper respiratory tract infections (URI) due to COVID, influenza or other viruses.The RD-X10 device is handheld, can be self-administered, and has been shown to be safe in invivo studies.
Eligibility criteria
Qualifiers
Active Duty and DoD Beneficiaries (i.e. former military, spouse, dependent child) aged 18 years and older who work in the Mike O'Callaghan Military Medical Center at Nellis Air Force Base.
Disqualifiers
Unable to comfortably insert RD-X19 into the mouth and keep in place for 5 minutes
Plans for head, neck or mouth surgery during the study period
Plans for major dental procedures (ie implants, wisdom teeth extraction etc) during the study
Trial design
Treatments tested in this trial
- RD-X19
- RD-X19 Sham
Treatment groups
130 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
David Moss
Lead sponsor
Mike O'Callaghan Military Hospital
Sponsor institution
Source ClinicalTrials.gov